{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:04:29Z","timestamp":1761930269986,"version":"3.44.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.diabres.2022.110043","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T13:48:05Z","timestamp":1660744085000},"page":"110043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Questions and answers on the use of aspirin for primary prevention of cardiovascular disease in diabetes"],"prefix":"10.1016","volume":"191","author":[{"given":"Ilaria","family":"Cavallari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Nobile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelio","family":"De Filippis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Veneziano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Maddaloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Paolo","family":"Ussia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Grigioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2022.110043_b0005","doi-asserted-by":"crossref","unstructured":"Patlak M. New weapons to combat an ancient disease: treating diabetes. FASEB J. 2002;16(14):1853. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12468446.","DOI":"10.1096\/fj.02-0974bkt"},{"key":"10.1016\/j.diabres.2022.110043_b0010","doi-asserted-by":"crossref","unstructured":"Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet (London, England). 2010;375(9733):2215-2222. doi:10.1016\/S0140-6736(10)60484-9.","DOI":"10.1016\/S0140-6736(10)60484-9"},{"issue":"14","key":"10.1016\/j.diabres.2022.110043_b0015","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.jacc.2021.02.030","article-title":"Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial","volume":"77","author":"Cavallari","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabres.2022.110043_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108008","article-title":"Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective","volume":"160","author":"Rocca","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2022.110043_b0025","article-title":"Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities","author":"Del Bianco-Rondeau","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.diabres.2022.110043_b0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality From Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabres.2022.110043_b0035","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1464-5491.2008.02640.x","article-title":"Is diabetes a coronary risk equivalent? Systematic review and meta-analysis","volume":"26","author":"Bulugahapitiya","year":"2009","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2022.110043_b0040","doi-asserted-by":"crossref","unstructured":"Antithrombotic Trialists\u2019 (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (London, England). 2009;373(9678):1849-1860. doi:10.1016\/S0140-6736(09)60503-1.","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"10.1016\/j.diabres.2022.110043_b0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ahj.2016.09.010","article-title":"Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy","volume":"182","author":"Grodzinsky","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.diabres.2022.110043_b0050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.amjcard.2022.01.057","article-title":"Association Between Platelet Reactivity and Long-Term Bleeding Complications After Percutaneous Coronary Intervention According to Diabetes Status","volume":"171","author":"Cavallari","year":"2022","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.diabres.2022.110043_b0055","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s11739-021-02640-z","article-title":"Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome","volume":"16","author":"Cavallari","year":"2021","journal-title":"Intern Emerg Med"},{"issue":"21","key":"10.1016\/j.diabres.2022.110043_b0060","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1001\/jama.2012.5034","article-title":"Association of aspirin use with major bleeding in patients with and without diabetes","volume":"307","author":"De Berardis","year":"2012","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.diabres.2022.110043_b0065","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non-sT-segment- elevation myocardial infarction the CRUSADE (can rapid risk stratification of unstable angina patients suppress ADverse outcomes with early implementation of the ACC\/AHA guidelines) bleeding score","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.diabres.2022.110043_b0070","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes","volume":"55","author":"Mehran","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"10073","key":"10.1016\/j.diabres.2022.110043_b0075","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.diabres.2022.110043_b0080","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","article-title":"Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (hypertension, abnormal renal\/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drug","volume":"57","author":"Lip","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.diabres.2022.110043_b0085","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/CIR.0b013e3181e3b133","article-title":"Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College","volume":"121","author":"Pignone","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2022.110043_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"issue":"18","key":"10.1016\/j.diabres.2022.110043_b0095","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.diabres.2022.110043_b0100","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus","volume":"379","author":"ASCEND Study Collaborative Group","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.diabres.2022.110043_b0105","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/CIRCULATIONAHA.116.025760","article-title":"Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial","volume":"135","author":"Saito","year":"2017","journal-title":"Circulation"},{"issue":"10186","key":"10.1016\/j.diabres.2022.110043_b0110","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/S0140-6736(19)30541-0","article-title":"The rise and fall of aspirin in the primary prevention of cardiovascular disease","volume":"393","author":"Raber","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2022.110043_b0115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41569-018-0080-2","article-title":"Statement Prevention of atherothrombotic events in patients with diabetes mellitus","volume":"16","author":"Patti","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"10.1016\/j.diabres.2022.110043_b0120","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.2337\/diabetes.54.8.2430","article-title":"Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment","volume":"54","author":"Angiolillo","year":"2005","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.diabres.2022.110043_b0125","first-page":"76","article-title":"Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease","volume":"100","author":"Serebruany","year":"2008","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.diabres.2022.110043_b0130","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jacc.2016.11.050","article-title":"Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus","volume":"69","author":"Bhatt","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.diabres.2022.110043_b0135","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.amjcard.2016.08.088","article-title":"Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus","volume":"118","author":"Gurbel","year":"2016","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.diabres.2022.110043_b0140","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.2337\/db07-0707","article-title":"The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study","volume":"56","author":"DiChiara","year":"2007","journal-title":"Diabetes"},{"issue":"14","key":"10.1016\/j.diabres.2022.110043_b0145","doi-asserted-by":"crossref","first-page":"E1910","DOI":"10.1016\/S0735-1097(11)61910-4","article-title":"Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease","volume":"57","author":"Capodanno","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.diabres.2022.110043_b0150","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJMx100069","article-title":"Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabres.2022.110043_b0155","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/dme.12828","article-title":"Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes","volume":"33","author":"Bethel","year":"2016","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2022.110043_b0160","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2102137","article-title":"Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease","volume":"384","author":"Jones","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabres.2022.110043_b0165","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"issue":"34","key":"10.1016\/j.diabres.2022.110043_b0170","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.diabres.2022.110043_b0175","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S2468-1253(18)30037-2","article-title":"Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials","volume":"3","author":"Scally","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.diabres.2022.110043_b0180","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.diabres.2022.110043_b0185","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2022.110043_b0190","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S125-S150. doi:10.2337\/dc21-S010.","DOI":"10.2337\/dc21-S010"},{"issue":"16","key":"10.1016\/j.diabres.2022.110043_b0200","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of Aspirin on All-Cause Mortality in the Healthy Elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.diabres.2022.110043_b0205","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11892-018-1117-y","article-title":"Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes","volume":"18","author":"Cavallari","year":"2018","journal-title":"Curr Diab Rep"},{"issue":"9435","key":"10.1016\/j.diabres.2022.110043_b0210","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.diabres.2022.110043_b0215","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering simvastatin in 5963 people with diabetes: a randomized controlled trial","volume":"361","author":"Heart Protection Study Collaborative Group","year":"2003","journal-title":"Lancet"},{"issue":"SUPPL. 2","key":"10.1016\/j.diabres.2022.110043_b0220","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003495-200464002-00005","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomi","volume":"64","author":"Sever","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.diabres.2022.110043_b0225","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019(CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins\u00a0: a meta-analysis. Lancet. 2008;371(January 12):117-125.","DOI":"10.1016\/S0140-6736(08)60104-X"},{"key":"10.1016\/j.diabres.2022.110043_b0230","doi-asserted-by":"crossref","unstructured":"Newman CB, Preiss D, Tobert JA, et al. Statin Safety and Associated Adverse Events A Scientific Statement from the American Heart Association. Vol 39.; 2019. doi:10.1161\/ATV.0000000000000073.","DOI":"10.1161\/ATV.0000000000000081"},{"issue":"2","key":"10.1016\/j.diabres.2022.110043_b0235","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.diabres.2022.110043_b0240","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.diabres.2022.110043_b0245","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2022.110043_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722008579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722008579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:23:36Z","timestamp":1759173816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822722008579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":49,"alternative-id":["S0168822722008579"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2022.110043","relation":{},"ISSN":["0168-8227"],"issn-type":[{"type":"print","value":"0168-8227"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Questions and answers on the use of aspirin for primary prevention of cardiovascular disease in diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2022.110043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110043"}}